333-253808) filed pursuant to Rule 462(b) under the Securities Act of 1933, as amended, on March 2, 2021, which registration statement became automatically effective upon filing.Ī final prospectus supplement relating to the offering dated Mawas filed with the SEC on Maand is available on the SEC’s website at. 333-235887) previously filed with the Securities and Exchange Commission (“SEC”) on January 10, 2020, which registration statement was declared effective on Januand an additional registration statement on Form S-3MEF (File No. The securities described above were offered by the Company pursuant to an effective shelf registration statement on Form S-3 (File No. and Colliers Securities LLC acted as co-managers for the offering. JMP Securities, Craig-Hallum Capital Group, and Lake Street Capital Markets, LLC acted as lead managers for the offering and Laidlaw & Company (UK) Ltd. Guggenheim Securities acted as sole book-running manager for the offering. The Company intends to use the net proceeds of the offering for working capital and general corporate purposes. The Company received total gross proceeds from the offering (before deducting the underwriting discounts and offering expenses) of approximately $25.0 million.
ICAD INVESTOR RELATIONS FULL
(the “Company”, NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced the closing on Maof its previously announced underwritten public offering of 1,393,738 shares of common stock at a public offering price of $18.00 per share, which included the exercise in full by the underwriters of their option to purchase up to an additional 171,516 shares of common stock. ICAD Receives FDA Approval for Digital CAD with Nice bounces today for ICAD and CVSL huh? Positive moving up lots of room to move 7.13 $ICAD Chart - BULLISH HARAMI reversal pattern is I hear that ICAD and SSH are competitors? Looking forward to hearing when Powerlook Tomo 2.0 $ICAD on the rise with imminent submission of ICAD just a beautiful breakout on this bio beast!!! News: $ICAD iCAD to Highlight ProFound AI(TM) SolutionĪI technology for cancer detection is very interesting. News: $ICAD SimonMed Imaging Implements the First FDA-Cleared News: $ICAD iCAD's ProFound AI(TM) for 2D Mammography
News: $ICAD iCAD Reports Second Quarter 2019 Financial Results
Very quiet board given the recent performance. JUST IN: $ICAD iCAD's IORT Excluded from CMS's Baby'sīreaking News: $ICAD iCAD Responds to CMS' Finalized Got out breakeven yesterday due to impending Death We have an industry-leading Research and Development team giving iCAD a strong base of intellectual property as is evident in the 22 CAD-related patents awarded and the additional 20 patents in process. For more information, call (877) iCADnow. iCAD’s solutions aid in the early detection of the most prevalent cancers including breast, colon, prostate and in the future, lung cancer. Since receiving FDA approval for the Company’s first breast cancer detection product in 2002, over 3,100 iCAD systems have been placed in healthcare practices worldwide.
iCAD offers a comprehensive range of high-performance, upgradeable Computer-Aided Detection (CAD) systems and workflow solutions for mammography (film-based, digital radiography (DR) and computed radiography (CR), Magnetic Resonance Imaging (MRI), and Computed Tomography (CT). is an industry-leading provider of advanced image analysis and workflow solutions that enable healthcare professionals to better serve patients by identifying pathologies and pinpointing cancer earlier.